Bristol Myers Squibb Reports Two-Year TRANSFORM Data for Breyanzi in Large B-Cell Lymphoma

Bristol Myers Squibb today presented two-year follow-up data from the Phase 3 TRANSFORM trial evaluating Breyanzi (lisocabtagene maraleucel) versus standard of care in patients with relapsed or refractory large B-cell lymphoma. The data showed that the event-free survival benefit of Breyanzi was maintained at two years, with 41% of patients in the Breyanzi arm event-free compared to 16% in the standard of care arm.